<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="105"><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>75</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Epidermal growth factor receptor; Programmed cell death 1 ligand 1</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>NKTR-214; atezolizumab; pembrolizumab</Interventions><Reference>16-214-05; NCT03138889; PROPEL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Brain tumor</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase Ib/II trial to evaluate the safety and efficacy of NKTR-214 in combination with entinostat, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent</ProtocolTitle><Sponsor>Syndax Pharmaceuticals Inc</Sponsor><TrialStatus>Planned</TrialStatus><Trial id="341373"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>Monocytes</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>NKTR-214; entinostat</Interventions><Reference>ENCORE 606</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic bladder cancer</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TAIL</ProtocolAcronym><ProtocolTitle>Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="87716"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>2</Patients><Biomarkers>B-CLL cells; IL-2</Biomarkers><Condition>Chronic lymphocytic leukemia</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/Maxcyte; allopurinol; lenalidomide</Interventions><Reference>H-30087 TAIL; NCT01604031; TAIL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Uterus tumor</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PIVOT-10</ProtocolAcronym><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="364590"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>165</Patients><Biomarkers>Programmed cell death 1 ligand 1; Programmed cell death 1 ligand 1</Biomarkers><Condition>Metastasis</Condition><Controls>carboplatin; gemcitabine</Controls><EnrollmentCount>165</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>18-214-10; CA045-012; NCT03785925; PIVOT-10</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EMD-273066; EMD-273066 (0.5 mg) + cyclophosphamide; EMD-273066 (1.0 mg) + cyclophosphamide; EMD-273066 (2.0 mg) + cyclophosphamide; EMD-273066 (3.0 mg) + cyclophosphamide; EMD-273066 (4.0 mg) + cyclophosphamide; cyclophosphamide</Interventions><Reference>EMR 62206-015; NCT00132522</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, bristol myers squibb international corporation belgium</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="350572"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>764</Patients><Biomarkers>Programmed cell death 1 ligand 1</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>764</EnrollmentCount><Interventions>NKTR-214; nivolumab; nivolumab</Interventions><Reference>17-214-08; 2018-001423-40; CA045-001; NCT03635983</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Lymphoplasmacytic lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Marginal zone B-cell lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 Plus Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="51498"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>13</Patients><Biomarkers>Chemokine; Chemokines; Cytokine; Interleukin-2 receptor; Leukocyte count; Neopterin</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>EMD-521873; Radiotherapy (5 x 4 Gy)</Interventions><Reference>EMR 62235-002; NCT00879866</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62646"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>CD4+; CD8+; Cytotoxic T-Lymphocytes; Lymphocytes; Natural killer (NK); Natural killer cells; Neopterin; T-Helper Lymphocytes; Thromboplastin time; sIL2R</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>NHS-IL2-LT; NHS-IL2-LT; cyclophosphamide</Interventions><Reference>EMR62235_001; NCT01032681</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread</ProtocolTitle><Sponsor>Masonic Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="74920"></Trial><Drug id="70160">salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Interleukin-2; Lymphocytes</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>salmonella-IL-2 cancer therapy (oral, cancer), Botanic Oil Innovations</Interventions><Reference>0906M68041; 2009LS003; NCT01099631; Protocol #0907-991</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic prostate cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A first-in-human, phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in selected patients with advanced/metastatic solid tumors</ProtocolTitle><Sponsor>Sotio AS</Sponsor><TrialStatus>Planned</TrialStatus><Trial id="352089"></Trial><Drug id="74941">SO-C101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>SO-C101; SO-C101; pembrolizumab</Interventions><Reference>SC103</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Angiosarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)</ProtocolTitle><Sponsor>Nektar Therapeutics, PPD Development (S) Pte Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="358884"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers></Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls>Cabometyx; Sutene</Controls><EnrollmentCount>600</EnrollmentCount><Interventions>NKTR-214; Opdivo</Interventions><Reference>17-214-09; 17-214-09 / CA045002; CA045002; NCT03729245</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Diffuse large B-cell lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>B-cell lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Cue Biopharma Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="383734"></Trial><Drug id="105120">CUE-101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>CUE-101</Interventions><Reference>CUE-101-01; NCT03978689</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic bladder cancer</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="184129"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD40 ligand; Granzyme B; Immunoglobulin G; Interferon gamma ; Interleukin-2; Interleukin-5</Biomarkers><Condition>Acute myelogenous leukemia</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Interventions><Reference>H6408-LEU LEU; NCT00058799</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic ovary cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Chondrosarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Merkel cell carcinoma</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I/IIa study to evaluate the safety and efficacy of AFTVac in patients with newly diagnosed glioblastoma multiforme</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="67525"></Trial><Drug id="55115">AFTVac</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers></Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>AFTVac</Interventions><Reference>C000000002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>interleukin-2; tucotuzumab celmoleukin</Interventions><Reference>CDR0000068612; EMD-EMR-62-206-003; MSKCC-00141; NCI-G01-1944; NCT00016237</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PORTER</ProtocolAcronym><ProtocolTitle>Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations</ProtocolTitle><Sponsor>Parker Institute for Cancer Immunotherapy</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="369648"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Circulating Tumor Cells; Prostate-specific antigen; Testosterone</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>CDX-301; NKTR-214; Stereotactic body radiation therapy 30 to 50 Gy; nivolumab; poly-ICLC</Interventions><Reference>NCT03835533; PICI0033; PORTER</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>IT-MATTERS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="73333"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>928</Patients><Biomarkers></Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls>Radiotherapy (60 to 70 Gy); cisplatin</Controls><EnrollmentCount>928</EnrollmentCount><Interventions>Multikine; Radiotherapy (60 to 70 Gy); cisplatin; cyclophosphamide; indomethacin; zinc</Interventions><Reference>2010-019952-35; CS001P3; CTRI/2011/05/001716; IT-MATTERS; NCT01265849; SLCTR/2014/017; UKCRN 16800</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-521873 in Advanced Solid Tumors, MTD Finding</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62646"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>CD4+; CD8+; Cytotoxic T-Lymphocytes; Lymphocytes; Natural killer (NK); Natural killer cells; Neopterin; T-Helper Lymphocytes; Thromboplastin time; sIL2R</Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>NHS-IL2-LT; NHS-IL2-LT; cyclophosphamide</Interventions><Reference>EMR62235_001; NCT01032681</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>75</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Epidermal growth factor receptor; Programmed cell death 1 ligand 1</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>NKTR-214; atezolizumab; pembrolizumab</Interventions><Reference>16-214-05; NCT03138889; PROPEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic esophageal cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic lung cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62586"></Trial><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>HLA class I histocompatibility antigen, A alpha chain; IL-2; p53</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>ALT-801 (bolus injection, cancer), Altor; cisplatin</Interventions><Reference>CA-ALT-801-02-09; NCT01029873; QUILT-2.008; R44CA097550</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Liposarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="360513"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>18-214-14; CA045-010; JapicCTI-184237; NCT03745807</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Carcinoma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>interleukin-2; tucotuzumab celmoleukin</Interventions><Reference>CDR0000068612; EMD-EMR-62-206-003; MSKCC-00141; NCI-G01-1944; NCT00016237</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of BAY-50-4798 in Patients With HIV Infection</ProtocolTitle><Sponsor>Bayer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13695"></Trial><Drug id="28450">AIC-284</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>82</Patients><Biomarkers>CD4(+) T cell</Biomarkers><Condition>HIV infection</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>BAY-50-4798</Interventions><Reference>10630; NCT00048191; NCT00059462</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, randomized, open-label, parallel-group study to assess the safety and efficacy of EMD-273066 following low-dose cyclophosphamide compared to supportive care alone in patients with small cell lung cancer</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89159"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Anti-EMD-273066 antibody</Biomarkers><Condition>Small-cell lung cancer</Condition><Controls>cyclophosphamide</Controls><EnrollmentCount>110</EnrollmentCount><Interventions>EMD-273066; cyclophosphamide</Interventions><Reference>2006-004566-13; EMR 62206-017</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PAW</ProtocolAcronym><ProtocolTitle>Study of Leukocyte Interleukin Injection for Treatment of Perianal Warts</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="286956"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>8</Patients><Biomarkers></Biomarkers><Condition>Condyloma</Condition><Controls></Controls><EnrollmentCount>8</EnrollmentCount><Interventions>Multikine</Interventions><Reference>NCT03038828; NMCSD2013.008_UCSF; PAW</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Leiomyosarcoma</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic pancreas cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Osteosarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>75</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Epidermal growth factor receptor; Programmed cell death 1 ligand 1</Biomarkers><Condition>Metastatic bladder cancer</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>NKTR-214; atezolizumab; pembrolizumab</Interventions><Reference>16-214-05; NCT03138889; PROPEL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Determine if Either of Two Doses of Study Drug Given With a Low-Dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-Based Second-Line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression</ProtocolTitle><Sponsor>EMD Pharmaceuticals Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="35819"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>EMD-273066; cyclophosphamide</Interventions><Reference>EMR 62206-016; NCT00408967</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ALT-801-Activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="82721"></Trial><Drug id="63685">ALT-801 (donor lymphocyte infusion, cancer), Altor</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Acute myelogenous leukemia</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>ALT-801 (donor lymphocyte infusion, cancer), Altor; G-CSF; cytarabine; fludarabine</Interventions><Reference>CA-ALT-801-02-08; NCT01478074</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic stomach cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PIVOT-10</ProtocolAcronym><ProtocolTitle>A Randomized Study of NKTR-214 Plus Nivolumab and of Reference Chemotherapy in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer With Low PD-L1 Expression</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="364590"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>165</Patients><Biomarkers>Programmed cell death 1 ligand 1; Programmed cell death 1 ligand 1</Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls>carboplatin; gemcitabine</Controls><EnrollmentCount>165</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>18-214-10; CA045-012; NCT03785925; PIVOT-10</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EMD-273066; EMD-273066 (0.5 mg) + cyclophosphamide; EMD-273066 (1.0 mg) + cyclophosphamide; EMD-273066 (2.0 mg) + cyclophosphamide; EMD-273066 (3.0 mg) + cyclophosphamide; EMD-273066 (4.0 mg) + cyclophosphamide; cyclophosphamide</Interventions><Reference>EMR 62206-015; NCT00132522</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EMD-273066; EMD-273066 (0.5 mg) + cyclophosphamide; EMD-273066 (1.0 mg) + cyclophosphamide; EMD-273066 (2.0 mg) + cyclophosphamide; EMD-273066 (3.0 mg) + cyclophosphamide; EMD-273066 (4.0 mg) + cyclophosphamide; cyclophosphamide</Interventions><Reference>EMR 62206-015; NCT00132522</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Metastatic ovary cancer</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Follicle center lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 Combined With Nivolumab versus Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, bristol myers squibb international corporation belgium</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="350572"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>764</Patients><Biomarkers>Programmed cell death 1 ligand 1</Biomarkers><Condition>Stage III melanoma</Condition><Controls></Controls><EnrollmentCount>764</EnrollmentCount><Interventions>NKTR-214; nivolumab; nivolumab</Interventions><Reference>17-214-08; 2018-001423-40; CA045-001; NCT03635983</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MSB-0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma</ProtocolTitle><Sponsor>EMD Serono Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="159844"></Trial><Drug id="57922">NHS-IL2-LT</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>12</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Forkhead box protein P3; Interleukin-7 receptor subunit alpha ; Leukocyte count; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>NHS-IL2-LT; Stereotactic Body Radiation therapy (24 Gy)</Interventions><Reference>EMR 062235-005; NCT01973608</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of Multikine in the Treatment of Perianal Warts</ProtocolTitle><Sponsor>United States Naval Medical Center, San Diego</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="182223"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>4</Patients><Biomarkers></Biomarkers><Condition>Condyloma</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>Multikine</Interventions><Reference>NCT02115919; NMCSD.2013.0080</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>interleukin-2; tucotuzumab celmoleukin</Interventions><Reference>CDR0000068612; EMD-EMR-62-206-003; MSKCC-00141; NCI-G01-1944; NCT00016237</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PROPEL</ProtocolAcronym><ProtocolTitle>A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="296922"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>75</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Epidermal growth factor receptor; Programmed cell death 1 ligand 1</Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>NKTR-214; atezolizumab; pembrolizumab</Interventions><Reference>16-214-05; NCT03138889; PROPEL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer</ProtocolTitle><Sponsor>Altor BioScience Corp</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="88603"></Trial><Drug id="57607">ALT-801 (bolus injection, cancer), Altor</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>52</Patients><Biomarkers>Anti-ALT-801; Cellular tumor antigen p53; HLA class I histocompatibility antigen, A alpha chain; HLA-A*0201/p53 aa 264 to 272; Interferon gamma; Interleukin-10; Interleukin-2 (IL-2); Interleukin-6; Tumor necrosis factor</Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>ALT-801 (bolus injection, cancer), Altor; gemcitabine; gemcitabine + ALT-801</Interventions><Reference>CA-ALT-801-01-12; NCT01625260</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EMD-273066; EMD-273066 (0.5 mg) + cyclophosphamide; EMD-273066 (1.0 mg) + cyclophosphamide; EMD-273066 (2.0 mg) + cyclophosphamide; EMD-273066 (3.0 mg) + cyclophosphamide; EMD-273066 (4.0 mg) + cyclophosphamide; cyclophosphamide</Interventions><Reference>EMR 62206-015; NCT00132522</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>EMD-273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given Cyclophosphamide</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28529"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Carcinoma</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>EMD-273066; EMD-273066 (0.5 mg) + cyclophosphamide; EMD-273066 (1.0 mg) + cyclophosphamide; EMD-273066 (2.0 mg) + cyclophosphamide; EMD-273066 (3.0 mg) + cyclophosphamide; EMD-273066 (4.0 mg) + cyclophosphamide; cyclophosphamide</Interventions><Reference>EMR 62206-015; NCT00132522</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REVEAL</ProtocolAcronym><ProtocolTitle>A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="329566"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>13</Patients><Biomarkers>CD8-Positive T-Lymphocytes; Cytotoxic T-Lymphocytes; Natural killer cells; T-Helper Lymphocytes</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>393</EnrollmentCount><Interventions>NKTR-214; NKTR-262; nivolumab</Interventions><Reference>17-262-01; NCT03435640; REVEAL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study in Patients With HPV+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Cue Biopharma Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="383734"></Trial><Drug id="105120">CUE-101</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Metastatic head and neck cancer</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>CUE-101</Interventions><Reference>CUE-101-01; NCT03978689</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Interleukin-2 combined with monoclonal antibody therapy in treating patients with kidney, bladder, or lung cancer that has not responded to previous treatment</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28011"></Trial><Drug id="21065">tucotuzumab celmoleukin</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>interleukin-2; tucotuzumab celmoleukin</Interventions><Reference>CDR0000068612; EMD-EMR-62-206-003; MSKCC-00141; NCI-G01-1944; NCT00016237</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>IT-MATTERS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral Cavity</ProtocolTitle><Sponsor>CEL-SCI Corp</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="73333"></Trial><Drug id="7401">Multikine</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>928</Patients><Biomarkers></Biomarkers><Condition>Metastatic head and neck cancer</Condition><Controls>Radiotherapy (60 to 70 Gy); cisplatin</Controls><EnrollmentCount>928</EnrollmentCount><Interventions>Multikine; Radiotherapy (60 to 70 Gy); cisplatin; cyclophosphamide; indomethacin; zinc</Interventions><Reference>2010-019952-35; CS001P3; CTRI/2011/05/001716; IT-MATTERS; NCT01265849; SLCTR/2014/017; UKCRN 16800</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II, Multicenter, Dose-Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268769"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Antigen KI-67; Chemokines; Cytokines; Granzyme B; Interferon gamma; Interleukin-2 receptor alpha chain ; Lymphocytes; Natural killer cells; Perforin-1; Programmed cell death protein 1; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor mass; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214</Interventions><Reference>15-214-01; 2015-0573; 2016-001134-10; NCT02869295</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>PIVOT-02</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="281291"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>283</Patients><Biomarkers>ALK receptor; B-Raf proto-oncogene serine/threonine-protein kinase; Cytotoxic T-Lymphocytes; Epidermal growth factor receptor; Inducible T-cell costimulator; Programmed cell death 1 ligand 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>480</EnrollmentCount><Interventions>Halaven; NKTR-214; NKTR-214 + Opdivo; Opdivo; Yervoy; carboplatin; cisplatin; nab-paclitaxel; paclitaxel; pemetrexed disodium</Interventions><Reference>16-214-02; 2016-003543-11; NCT02983045; PIVOT-02</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treating High Risk Leukemia With CD40 Ligand and IL-2 Gene Modified Tumor Vaccine</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="184129"></Trial><Drug id="45937">autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD40 ligand; Granzyme B; Immunoglobulin G; Interferon gamma ; Interleukin-2; Interleukin-5</Biomarkers><Condition>Myelodysplastic syndrome</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>autologous IL2 and CD40 ligand-expressing tumor cells (B-CLL), Baylor College of Medicine</Interventions><Reference>H6408-LEU LEU; NCT00058799</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PIVOT-09</ProtocolAcronym><ProtocolTitle>A phase III clinical study to assess the effect of bempegaldesleukin in combination with nivolumab compared to tyrosine kinase inhibitor (TKI) monotherapy in patients with advanced metastatic renal cell carcinoma</ProtocolTitle><Sponsor>Nektar Therapeutics</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="372111"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Metastatic renal cell carcinoma</Condition><Controls>tyrosine kinase inhibitor (TKI) monotherapy</Controls><EnrollmentCount></EnrollmentCount><Interventions>bempegaldesleukin; nivolumab</Interventions><Reference>PIVOT-09</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-1</ProtocolAcronym><ProtocolTitle>A Study of the Effects of ALKS-4230 on Subjects With Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="263216"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Creatinine; Cytokines; Cytotoxic T-Lymphocytes; Interferon gamma; Interleukin-6; Leukocyte count; Lymphocytes; Mononuclear leukocytes; Natural killer cells; Neutrophils; Regulatory T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; pembrolizumab</Interventions><Reference>ALK4230-A101; ARTISTRY-1; NCT02799095</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Leiomyosarcoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312527"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Histiocytoma</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>NKTR-214; nivolumab</Interventions><Reference>17-366; CA209-9EM; NCT03282344</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="337393"></Trial><Drug id="77588">bempegaldesleukin</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Mantle cell lymphoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>NKTR-214; TAK-659</Interventions><Reference>C34015; NCT03772288; U1111-1218-4372</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARTISTRY-2</ProtocolAcronym><ProtocolTitle>A Dose-Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS-4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="372173"></Trial><Drug id="86441">ALKS-4230</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>230</Patients><Biomarkers>Cytokines; Mononuclear leukocytes</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>230</EnrollmentCount><Interventions>ALKS-4230; ALKS-4230; Keytruda</Interventions><Reference>ALKS 4230-001; ARTISTRY-2; NCT03861793</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>